Nkarta, Inc.
NASDAQ:NKTXBiotechnology
+$0.09 today
- Market cap
- $82.37M
- Beta
- 0.90
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.35
Volume 0.81M
Average 0.75M
NKTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Nkarta, Inc.NASDAQ: NKTX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $22.65M fell 6.3% year over year, ahead of the -7.1% change in trailing-twelve-month research & development. Sequentially, it fell 10.4% from the prior quarter. Over 3 fiscal years it compounded at -0.2% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -6.3% holds above the trailing-twelve-month pace of -7.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 90.43M USD
- Year-over-year change
- -6.5%
- 4-year CAGR
- +9.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 90.43M | -6.5% |
| FY2024 | 2024-12-31 | 96.74M | +6.4% |
| FY2023 | 2023-12-31 | 90.9M | +0.0% |
| FY2022 | 2022-12-31 | 90.9M | +43.3% |
| FY2021 | 2021-12-31 | 63.41M | — |
Research & Development vs competitors
How NKTX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.1% is the 4th highest of 8, against a peer median of -23.9%.
- Over three fiscal years its annual growth of -0.2% compares with a peer median of +9.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $312.43M USD | +226.5% | +70.8% | — | |
| LTM Mar 2026 | $114.68M USD | -37.7% | -16.4% | 622.7% | |
| LTM Mar 2026 | $100.48M USD | -23.9% | -30.4% | 1590.8% | |
| LTM Mar 2026 | $88.91M USD | -7.1% | -0.2% | — | |
| LTM Mar 2026 | $65.43M USD | +123.8% | +118.4% | — | |
| LTM Mar 2026 | $58.35M USD | -32.7% | +9.5% | — | |
| LTM Mar 2026 | CHF 46.97M CHF | -1.7% | -7.5% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $23.84M USD | -29.5% | +13.5% | — |
| Peer median (excluding NKTX) | — | -23.9% | +9.5% | 1106.8% | |
Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 5.87M | 0 | 9.19M |
| Gross Profit | 0 | 0 | (5.87M) | 0 | (9.19M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 63.41M | 90.9M | 90.9M | 96.74M | 90.43M |
| Selling, General & Admin | 23.02M | 28.06M | 34.88M | 31.45M | 31.57M |
| Operating Expenses | 86.43M | 118.96M | 125.78M | 128.19M | 112.01M |
| Depreciation & Amortization | 1.76M | 2.64M | 5.87M | 9.15M | 9.19M |
| EBITDA | (84.32M) | (105.61M) | (120.48M) | (99.64M) | (94.89M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (86.43M) | (118.96M) | (131.65M) | (128.19M) | (121.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 370K | 5.59M | 14.11M | 19.32M | 15.49M |
| Interest Expense | 0 | 5.59M | 0 | 0 | 0 |
| Other Income / Expenses | 354K | 5.12M | 14.15M | 19.4M | 17.12M |
| Income Before Tax | (86.08M) | (113.84M) | (117.5M) | (108.79M) | (104.08M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (86.08M) | (113.84M) | (117.5M) | (108.79M) | (104.08M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.62) | (2.61) | (2.40) | (1.60) | (1.41) |
| EPS (Diluted) | (2.62) | (2.61) | (2.40) | (1.60) | (1.41) |
| Weighted Avg Shares | 32.86M | 43.63M | 49.01M | 67.87M | 73.99M |
| Weighted Avg Shares (Diluted) | 32.86M | 43.63M | 49.01M | 67.87M | 73.99M |
Nkarta, Inc.
NASDAQ:NKTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.